Compounds > naltrexone

naltrexone and Parkinson Disease, Secondary

naltrexone has been researched along with Parkinson Disease, Secondary in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bédard, PJ; Grégoire, L; Samadi, P1
Brotchie, JM; Crossman, AR; Maneuf, YP; Mitchell, IJ; Woodruff, GN1
Flumerfelt, BA; Newman, DD; Rajakumar, N; Stoessl, AJ1
Brotchie, JM; Hill, MP1

Other Studies

4 other study(ies) available for naltrexone and Parkinson Disease, Secondary

ArticleYear
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
    Neuropharmacology, 2003, Volume: 45, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission

2003
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.
    Brain research, 1995, Jun-12, Volume: 683, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Arrhythmia Agents; Basal Ganglia; Benzofurans; Callithrix; Female; Glutamic Acid; In Vitro Techniques; Male; Motor Activity; Naltrexone; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine; Synaptic Transmission

1995
A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease.
    Neuroreport, 1997, Feb-10, Volume: 8, Issue:3

    Topics: Animals; Apomorphine; Functional Laterality; Hippocampus; Infusions, Parenteral; Levodopa; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation

1997
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
    British journal of pharmacology, 1999, Volume: 128, Issue:7

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzofurans; Biogenic Monoamines; Clonidine; Disease Models, Animal; Drug Combinations; Drug Synergism; Locomotion; Male; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Prazosin; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine; Yohimbine

1999